---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-202313"
form_type: "8-K"
ticker: "ALNY"
cik: "0001178670"
company_name: "ALNYLAM PHARMACEUTICALS, INC."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:18:23.122627+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alnylam Q2 net product revenues up 43% to $306M; Vaishnaw steps down as President

## Summary
- Net product rev $306M (+43% YoY); GAAP net loss $276M ($2.21/share), non-GAAP net loss $202M ($1.62/share).
- AMVUTTRA rev $132M, ONPATTRO $91M, GIVLAARI $58M, OXLUMO $24M; total TTR growth 72% in U.S.
- Reiterated 2023 guidance: combined net product rev $1.2B-$1.285B.
- U.S. Attorney's Office closed ONPATTRO marketing investigation with no action.
- President Akshay Vaishnaw transitions to part-time Chief Innovation Officer, effective Oct 2, 2023.

## SEC filing metadata
- accession: 0001193125-23-202313
- form_type: 8-K
- ticker: ALNY
- cik: 0001178670
- company_name: ALNYLAM PHARMACEUTICALS, INC.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178670/000119312523202313/0001193125-23-202313-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178670/000119312523202313/d472276d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-202313
- JSON: https://secwatch.observer/filing/0001193125-23-202313.json
- Plain text: https://secwatch.observer/filing/0001193125-23-202313.txt

## Key facts
- Earnings Releases
  ALNYLAM PHARMACEUTICALS, INC. updated its the second quarter ended June 30, 2023 guidance (reaffirmed).
  - Period: the second quarter ended June 30, 2023
  - Guidance: reaffirmed
  - Result: reported results
  source text: On August 3, 2023, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000119312523202313/0001193125-23-202313-index.htm
- Executive change
  Akshay K. Vaishnaw changed role as Chief Innovation Officer at ALNYLAM PHARMACEUTICALS, INC..
  - Action: transitioned
  - Role: Chief Innovation Officer
  source text: On July 31, 2023, the Company and Akshay K. Vaishnaw, M.D., Ph.D. entered into a letter agreement (the “Letter Agreement”), whereby Dr. Vaishnaw will leave his current position as President of the Company and transition to a part-time role as Chief Innovation Officer, effective October 2, 2023 (the “Transition Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178670/000119312523202313/0001193125-23-202313-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.